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The tumor suppressor protein p53 controls cell cycle
checkpoints and apoptosis via the transactivation of
several genes. However, data from various laboratories
suggest an additional role for p53: transcription-inde-
pendent suppression of homologous recombination
(HR). Genetic and physical interactions among p53, HR
proteins (e.g. RAD51 and RAD54) and HR-DNA inter-
mediates show that p53 acts directly on HR during the
early and late steps of recombination. Complementary
to the MSH2 mismatch-repair system, p53 appears to
impair excess HR by controlling the minimal efficiency
processing segment and by reversing recombination
intermediates. By controlling the balance between the
BLM and the RAD51 pathways, this direct role of p53
could maintain genome stability when replication forks
are stalled at regions of DNA damage. In this article, we
discuss the direct role of p53 on HR and the conse-
quences for genome stability, tumor protection and
speciation.
Faithful genome transmission requires the co-ordination
of a network of pathways including CELL CYCLE CHECK-
POINT (see Glossary), DNA repair-recombination and
apoptosis. This network prevents the proliferation of
cells bearing damaged DNA.
The tumor suppressor gene p53 (TP53) is the most
frequently mutated gene found in tumors [1,2]. Following
genotoxic stress, the p53 protein transactivates a collec-
tion of genes that control the cell cycle checkpoint and
apoptosis [3]. However, studies from different laboratories
have pointed to an additional role of p53: transactivation-
independent negative regulation of homologous recombi-
nation (HR).
Precise control of HR is essential to ensure the
stability–variability equilibrium of the genome. HR is
considered as an error-free DNA repair system because it
copies an intact homologous sequence (Box 1). However,
HR can also become deleterious and in excess it can
promote genome instability and cause disease [4]. CROSS-
ING OVER (a product of HR) between dispersed repetitive
sequences can lead to different types of genome rearrange-
ments (Figure 1a). GENE CONVERSION (a product of HR)
with the homologs can lead to loss of heterozygosity [5],
whereas gene conversion with a pseudogene, which gene-
rally bears stop mutations, can inactivate a functional
allele [6] (Figure 1b). Moreover, the accumulation of aber-
rant abortive recombination events can also be toxic [7,8].
In addition to genetic interactions, the demonstration of
physical interactions between p53 and proteins that are
involved in recombination or DNA-recombination inter-
mediates reveals a direct role for p53 in the control of
genome stability. But how does p53 exert this effect? In this
article, we present the data showing that p53 does not
work via transactivation and we discuss the consequences
for genome stability control, tumor protection and speciation.
Wild-type p53 represses gene conversion independently
of its transactivation activity
p53 affects spontaneous and induced HR – impact on the
RAD51-gene conversion pathway
The impact of p53 on HR has been studied in human,
monkey and rodent adult or embryonic cells. Different
methods of p53 inactivation have been used including:
(i) the deletion of p53; (ii) the inactivation by the
p53-antagonist HDM2 (the human homolog of mouse
double minute 2) or by viral proteins such as large
T antigen from SV40 or E6 of papilloma virus; (iii) the
inactivation of temperature-sensitive p53; or (iv) the
expression of dominant negative mutant p53. All of
these studies concluded that wild-type (wt) p53 represses
HR. In apparent contrast, it has been reported that
RAD51-dependent gene targeting (by HR) is independent
of p53 status in ES cells [9]. However, p53 is located in the
cytoplasm in ES cells and is unlikely to affect nuclear
events either directly or via its transactivation activity [10].
Glossary
Cell cycle checkpoint: cellular process that stops or slows the cell cycle in
conditions that are unfavorable for cell division.
Crossing over: the reciprocal exchange of genetic information (Box 1).
Gene conversion: the non-reciprocal exchange of genetic information, which
does not modify the general chromosome structure (Box 1).
Heteroduplexes: duplex-hybrid DNA, generated by strand exchange (Box 1)
and containing mismatches.
Holliday junctions: cruciform intermediates generated by strand exchange at
initiation step of homologous recombination (Box 1).
Paralogs: genes within the same species that share structural homology –
probably generated by the duplication of an ancestral gene.
Corresponding author: Bernard S. Lopez (blopez@cea.fr).
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Two main methods have been used to measure HR. The
first method measures the intermolecular HR between two
defective SV40 genomes with HR recreating a functional
viral genome [11]. The second strategy measures intra-
molecular HR between tandem repeat sequences, which
restores a functional reporter gene [12–18]. Most studies
have been conducted in cultured cells but recently the
question has been addressed in vivo in mice [17].
Inhibition of p53 stimulates HR between direct repeats
and between inverted repeat sequences [18]. Because
recombination between inverted repeats mainly involves
gene conversion [19], this suggests that p53 affects gene
conversion, which is a RAD51-dependent process in
mammalian cells [20].
Double-strand break (DSB) repair
DSBs strongly stimulate HR in mammalian cells [21].
However, ionizing radiation induces DSBs but it does not
stimulate significantly HR in wt-p53 cells [18,22], whereas
it strongly stimulates HR when these cells contain
mutant p53 [16,18]. More precisely, on an enzymatic
DSB that is targeted in the recombination substrate by the
Box 1. Homologous recombination: roles, mechanisms and products
Homologous recombination (HR) is a fundamental process that is
conserved in all organisms and involved in genome stability, molecular
evolution, chromosome segregation during meiosis, DNA repair and
resumption of stalled replication forks [31,64,65].
In most models, HR is initiated at a break or a nick on one DNA
molecule followed by exchanges with an intact homologous DNA
partner, which can be found on the sister chromatid, leading to sister
chromatid exchange (SCE) on the homologous chromosome or on
repetitive sequences that are dispersed through the genome. The most
documented model is the double-strand break (DSB) repair model
(Figure I), which accounts for DSB repair after genotoxic stress, during
meiotic recombination or gene targeting.
The two products of HR are gene conversion that is associated with
crossing over or gene conversion without associated crossing over
(Figure I). Both types of products are initiated by the same initial step:
homologous pairing and strand exchange catalyzed by RecA protein in
bacteria or by RAD51 in eukaryotes [66–68].
Figure I. Double-strand break (DSB) repair via homologous recombination:
the DSB repair model [69]. (i) The DSB is processed by a single-strand exo-
nuclease generating single-stranded tails. This process is believed to be cata-
lyzed by the heterotrimer RAD50–MRE11–NBS1. (ii) The single-stranded
DNA, coated with RAD51, aligns and invades a homologous duplex DNA. This
step requires sequence homology but limited polymorphism is tolerated.
Consequently, if strand exchange occurs between non-perfectly homologous
sequences (bearing some sequence divergences), it creates heteroduplexes
that can be processed by the mismatch-repair system. This step also creates
cruciform junctions (Holliday junctions), which can migrate (branch migra-
tion) leading to the elongation of the heteroduplex molecule. (iii) RAD54 acts
in the subsequent steps: polymerization is primed from the 30 invading strand;
displaced single-stranded DNA then anneals the complementary single-
stranded tail. (iv) Polymerization fills in the gaps. (v) Gene conversion
depends on the orientation of mismatch repair of the heteroduplex and on the
sequence copied at the DSB location. Holliday junctions can be resolved
according to two alternative orientations (black or white triangles). Depending
on the orientation of the resolution of the Holliday junctions, the products
(gene conversion) will be associated or not with crossing over. Abbreviations:
NBS1, Nijmegen breakage syndrome 1; MRE11, MRE11 meiotic recombi-
nation 11 homolog.
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meganuclease I-SceI, wt p53 strongly inhibits HR [23].
Importantly, ionizing radiation-induced HR is controlled
via a RAD51 pathway in mammalian cells [20]. These data
also identify the RAD51 pathway as a target for HR
suppression by wt p53.
p53 affects HR independently of its role in the G1–S
checkpoint and in transactivation activity
Replication (in S-phase) of damaged DNA leads to genetic
instability. Following genotoxic stress, p53 protein is stab-
ilized and transactivates a collection of genes that leads to
the arrest of the damaged cells in G1, prior to the S-phase.
This arrest enables repair of the DNA matrix before
replication, thereby avoiding genetic instability [3]. This
role of genome-integrity maintenance is thus dependant
on the p53 transactivation activity. Paradoxically, treat-
ment with hydroxyurea (a replication inhibitor) stabilizes
the p53 protein without triggering its transactivation
activity [24], suggesting the importance of a transcription-
independent role for p53 in genome maintenance during
replication.
Several studies showed that the suppression of HR by
p53 is a function that is separate from its G1-arrest control
and transactivation activities [18,25–27].
In addition, HR is stimulated by RAD51 overexpression
but this stimulation is inhibited by co-expression of a
transcriptionally inactive p53 mutant, confirming both the
interaction with the RAD51 pathway and the indepen-
dence of p53-transactivation activity [28,29].
Figure 1. (a) Possible chromosome rearrangements resulting from crossing over (CO) between repeated dispersed sequences. (i) Inter-chromosomal CO or unequal
sister-chromatid exchange leading to deletion and amplification. (ii) Intrachromatid CO between direct repeats leading to deletion and an excised fragment. The excised
fragment can be eliminated or randomly re-integrated into the genome [20]. (iii) Intrachromatid CO between inverted repeats leading to the inversion of the intervening
sequence. (iv–v) Interchromosomal CO. Depending on the orientation with regard to the centromeres, these events result in translocation (iv) or in dicentric plus acentric
chromosomes (v). (b) The consequences of gene conversion between two hetero-alleles (i) or with a pseudogene (ii). The red boxes represent the mutations and the green
box represents the pseudogene.
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Role in stalled replication forks
HR is an efficient way of reactivating blocked replication
forks [30,31]. Replication elongation inhibitors such as
hydroxyurea and aphidicolin stimulate RAD51-dependent
recombination [32], which is repressed by wt p53 [33,34].
Recently, it has been reported that the Bloom syndrome
protein (BLM; Box 2) facilitates the transport of p53 to the
stalled replication forks and facilitates the interaction
with RAD51 [28]. The authors propose a model in which
p53 controls the alternative processing of stalled replica-
tion forks (i.e. BLM or RAD51–RAD54) and by repressing
HR limits HR-induced genetic instability (Figure 2).
Remarkably, both the transactivation-dependent (G1
arrest) and transactivation-independent (HR repression)
roles of p53 pursue the same goal: the prevention of genetic
instability resulting from the replication of damaged DNA.
These two processes could thus represent back-up systems.
Requirements of p53 for HR suppression: dosage,
mutations and structural domains
Low expression levels of wt p53 are sufficient for HR
suppression [23]. Reciprocally, low expression levels of
dominant-negative p53 are sufficient to stimulate HR [18].
Mutations in p53 stimulate HR but to a lesser degree
than its complete inactivation. In addition, p532/2 mouse
embryonic fibroblasts (MEFs) exhibit higher levels of HR
than p53þ/þ MEFs. Interestingly, p53þ/2 MEFs exhibit an
intermediate response, showing that p53 is haploinsuffi-
cient for HR suppression [16].
Box 2. The RecQ family in mammalian cells
The RecQ proteins contain a specific helicase domain conserved
through evolution and define the RecQ family (Figure I). The Rec Q
helicase family comprises the bacterial RecQ, the yeast Sgs1 and five
members in mammalian cells: BLM, WRN, RTS (the mutated protein
in Rothmund–Thompson syndrome), RecQ4 and RecQ5. WRN is a
helicase affected in Werner syndrome (WS), an autosomal recessive
disorder that is associated with genetic instability, cancer predisposition
and with premature aging. BLM is a helicase affected in Bloom syn-
drome (BS), an autosomal recessive disorder that is associated with
genetic instability and cancer predisposition. BS is characterized by
elevated levels of sister-chromatid exchange. Both BLM and WRN have
been reported to process Holliday junctions [70] and WS cells are
defective in recombination intermediate processing [8].
Figure I. RecQ family members. The blue boxes correspond to the conserved RecQ helicase domain. WRN possesses also an exonuclease domain (red box) absent
in the other family members. The numbers on the right part indicate the number of amino acids in the corresponding protein. Abbreviations: BLM, Bloom syndrome
protein; RTS, Rothmund–Thompson syndrome protein; RecQ4, RecQ protein-like 4; RecQ protein-like 5; WRN, Werner syndrome protein.
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Figure 2. A model of the direct role of p53 on stalled replication forks [28]. (i) Replication is blocked, possibly by DNA damage (brown square), such as DNA adducts (after
chemical stresses) or kinky lesions (UV-C irradiation) (ii) The neo-synthesized strands (in red) are complementary to each other and can thus anneal, creating a chicken foot
structure. This structure is reminiscent of a Holliday junction and can branch migrate or be resolved leading to double-strand breaks (DSBs) Two alternative pathways can
process such a structure: (iii) Bloom syndrome protein (BLM) can reverse branch migration, maintaining genome stability; (iv) the DSB is repaired by RAD51–RAD54
pathway leading to a recombinogenic repair. In line with this evidence, a defect in BLM results in high levels of spontaneous sister-chromatid exchange. P53 controls both
process and orientates between the two alternative processes. It has thus been named a ‘molecular governor’ [28].
TRENDS in Genetics 
BLM
RAD51
RAD54
p53
Stalled replication fork(i)
(ii)
(iii) Reverse branch migration
(iv) Homologous recombination
Review TRENDS in Genetics Vol.20 No.6 June 2004238
www.sciencedirect.com
The p53 protein possesses several domains (Figure 3a).
The core domain is implicated in the interaction with
the p53-specific DNA-responsive elements, whereas the
C-terminal domain is involved in the interaction with
non-specific sequences.
A structurally intact core domain and the oligomeriza-
tion domain are required for the control of HR by p53 [18,25].
By contrast, the C-terminal domain is not essential for
HR suppression [25,26]. However, different activities have
been attributed to the C-terminal amino acids: binding or
annealing of single-stranded DNA, recognition of DNA
damage or recognition of particular structures [35]. More
specifically, this domain is involved in the localization of
p53 to stalled replication forks [28], in the interaction with
the recombination protein RAD54 [29] and in the proces-
sing of HR intermediates [25,36].
Thus, the core and the C-terminal domains of p53 might
participate, using parallel pathways, in HR regulation.
Physical interactions of p53 with HR proteins and HR
intermediates
In accordance with the genetic interactions and with
cytological colocalization, physical interactions between
p53 and the RAD51 and RAD54 recombination proteins
have been shown in vitro and in vivo [28,29,37,38]. These
data are thus consistent with p53 having a role in HR that
is independent of its transactivation activity.
The interaction domain of p53
The domains of p53 that interact with RAD51 are located
at each edge of the core region: at amino acid 94–160 and
at amino acid 264–315 [38] (Figure 3a), which is consistent
with the core domain being essential for HR repression.
Interestingly, this core region contains cancer-mutation
hotspots. The p53–RAD54 interaction domain is located in
the C-terminal domain [29].
Interaction domain of RAD51
The RAD51 core domain, which is highly conserved from
bacteria to mammals, contains catalytic residues for ATP
binding-hydrolysis and is involved in the homo-oligomer-
ization of RAD51, two processes essential for HR. The
interaction domains have been mapped (amino acid
125–220) [38] and span the region from the first to the
second ATP box corresponding to the ‘RecA fold’
(Figure 3b). By interacting with the ‘RecA fold’ of
RAD51, p53 is likely to affect RAD51 activity.
p53 inhibits HR through physical interaction with RAD51
The overexpression of either wt RAD51 or mutant
L186PRAD51, which exhibits reduced binding to p53,
stimulates HR. P53 prevents stimulation of HR by wt
RAD51 but not by L186PRAD51, suggesting that p53
represses HR through physical interaction with RAD51 [29].
Recently, molecular and biochemical support for these
data has emerged. In in vitro reactions that used one
single-stranded homologous DNA molecule and one
double-stranded homologous DNA molecule, p53 inhibited
the initiation of strand invasion (Box 1) promoted by
human RAD51 or bacterial RecA proteins. In addition, on
assembled strand-exchange intermediates (Box 1), p53
impaired branch migration promoted by human Rad51
but not by RecA, thus, exhibiting its specificity for the
mammalian protein. Consistent with genetic studies
mutant p53, which does not repress HR in vivo, failed to
inhibit the in vitro reactions [39].
Taken together, these data indicate that physical
interactions between RAD51 and p53 are necessary for
Figure 3. Structural domains of p53 and RAD51. (a) Functional domains of p53. The RAD51 binding domains are indicated. (b) Human HsRAD51 and bacterial RecA. The
evolutionarily conserved core domain is shown in yellow. The gray boxes correspond to the ATP-binding sites. The ‘RecA fold’ and the p53-binding domain are indicated.
The numbers correspond to the amino-acid residue positions. Abbreviation: NLS, nuclear localization sequence.
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the inhibition of strand exchange and HR. These results
are consistent with the location of the p53–RAD51
interaction domains.
Interactions with other proteins of the HR complex
RAD51 is assisted in HR regulation by many partners in
elaborate proteins complex(es). In addition to five RAD51
PARALOGS, RAD51 also interacts with many other proteins
that also control HR and for which physical interactions
with p53 have been described (Figure 4a). Thus, p53 could
act on HR via an interaction with one or several of the
RAD51 partners.
Moreover, it has been proposed that the highly ordered
chromatin structure has a role in HR regulation by p53
[40]. In addition to the protein interactions, several studies
show the binding of p53 protein to recombination
intermediates, which results from the strand-exchange
process, such as HETERODUPLEXES and HOLLIDAY
JUNCTIONS (Box 1).
p53 binds to HR intermediates: a comparison with the
MSH2 mismatch repair system
MSH2, which is implicated in hereditary nonpolyposis
colorectal cancer, and p53 have many common and parallel
characteristics. MSH2, in association with a related
protein MSH6, has a pivotal role in the repair of the
mismatched bases that occur during replication. Inacti-
vation of mismatch repair (MMR) results in a mutator
phenotype and in tumor predisposition [41]. Because
MMR corrects heteroduplexes that have mismatches this
system reverses gene conversion products, which results
in HR downregulation. Thus, both MSH2 and p53 have
roles in tumor suppression and in HR suppression.
Immunoprecipitation and immunocytofluorescence
have revealed physical interactions and colocalization of
p53 and MSH2, which overlap RAD51 foci during the
S phase of the cell cycle. [42]. Moreover, both p53 and
MSH2 interact with the same kinds of HR intermediates,
as discussed in the following sections.
(i) Heteroduplexes. Similarly, MSH2 and p53 associate
with duplex DNA to form complexes that become highly
stable after encountering mismatches [43]. However, p53
and the MMR factor do not exhibit the same affinity for
different mismatches. For instance, the C–C mismatch
was the best recognized by p53 and the worst recognized
by human heterodimer hMSH2–hMSH6. By contrast,
the G–T mismatch was the best recognized by
hMSH2–hMSH6 and the worst recognized by p53 [44].
However, the two systems can also cooperate because
hMSH2–hMSH6 enhances p53 binding to DNA substrates
that have bulged bases [45].
Strand invasion generated by RAD51 (Box 1) produces
a three-strand intermediate, a structure for which p53
exhibits high affinity particularly when it contains mis-
matches [46]. In contrast to hMSH2–hMSH6, a prefer-
ential recognition of C–T versus G–T mispairing has been
observed for p53. In vivo HR experiments, designed to
generate heteroduplexes with distinctly mispaired regions,
showed that inhibition of HR by p53 was dependent on the
type of mismatch that was present in the heteroduplex and
correlates with the affinity of the in vitro binding of p53 to
artificial recombination intermediates [46].
A 30 ! 50 exonuclease activity has also been reported for
p53 [47]. Three-stranded intermediates represent good sub-
strates for this activity, particularly when they comprise
mismatches, and seem to be stimulated by RAD51. The
authors suggest that the RAD51–p53 interaction has a role
in targeting p53 to mismatched heteroduplexes and that p53
downregulates HR by nucleolytic degradation of hetero-
duplexes containing mismatches [48].
(ii) Holliday junctions. In vitro, p53 protein interacts
with Holliday junctions [36]. In parallel, the human
Figure 4. Targets of p53 for homologous recombination (HR) control. (a) HR
protein complexes in mammalian cells. (i) Five paralogs of RAD51 (XRCC2, XRCC3,
RAD51B, RAD51C and RAD51D), in two different complexes act on HR. However,
no physical interactions between these paralogs and RAD51 or p53 have been
clearly demonstrated. (ii) RAD51 also interacts physically with proteins controlling
HR. Those shown in blue have been shown to interact physically with p53. (b) After
strand exchange, which is promoted by RAD51, the heteroduplex contains
mismatches (black dots), p53 (or MSH2) reverses this intermediate. (c) P53 could
also act on the Holliday junction. Abbreviations: BRCA1, breast cancer 1 early
onset; BRCA2, breast cancer 2 early onset; BLM, Bloom syndrome protein; MSH2,
mutS homolog 2 colon cancer nonpolyposis type 1; RPA, replication factor A;
WRN; Werner syndrome protein; XRCC2, X-ray repair complementing defective
repair in Chinese hamster cells 2; XRCC3, X-ray repair complementing defective
repair in Chinese hamster cells 3.
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hMSH2–hMSH6 dimer also interacts with Holliday
junctions and facilitates the binding of p53 to these
junctions [45].
Consistent with these data, p53 interacts with the two
RecQ family helicases, BLM and the Werner syndrome
protein (WRN) [49–53]. In addition, the C-terminal region
(residue 373–383) is required for interaction with BLM
and WRN and for modulation of their branch migration
activities [53]. In in vitro reactions, p53 inhibits the
helicase activity of BLM and WRN on a four-arm 50-mer
X-junction that is supposed to mimic Holliday junctions.
Interestingly, p53 cancer-hotspot mutants (residue 273 or
248), which do not repress HR, show a lack of (273H) or a
decreased (248W) inhibitory effect on the helicase activity
of BLM or WRN.
Control of the minimal efficiency processing segment
(MEPS): impact on genome stability and on speciation
Impact on genome stability
Recombination between repeat sequences could represent
a potential danger for genome integrity. However, repeat
sequences and non-coding sequences exhibit frequently
sufficient divergences to prevent an excess of recombina-
tion. Efficient HR requires a segment of uninterrupted
homology between the two recombining molecules: the
minimal efficiency processing segment (MEPS).
In mammalian cells, the MEPS comprises 200–300 bp
[54]. Importantly, studies on the stability of repetitive
sequences propose that p53 creates a threshold for the
length of homology for recombination [15]. Remarkably,
p53 is more active in suppressing HR when the homology
segment is,200 bp [23]. Thus, we propose that p53 might
constitute an additional method of securing genome
maintenance by controlling the MEPS.
Speculation: impact on speciation?
Recombination between the genomes of two closely
related species should be impaired by the sequence
divergences, which represent a genetic barrier. How-
ever, the genetic barrier between Escherichia coli
and Salmonella typhimurium, which are separated by
100–150 million years and show 15% divergence, has been
overcome by the inactivation of the MMR system [55]. It
has been suggested that neutral polymorphisms might
function as genetic barriers enabling the participation of
MMR in speciation [55,56]. If in a complementary and
parallel way to MSH2, p53 is part of an anti-HR system
(by mismatch correction and controlling the MEPS),
it is tempting to speculate that it might also participate
in speciation.
Control of HR by p53 and tumor protection?
The transactivation activity of p53 has a pivotal role in at
least two tumor prevention processes: cell cycle checkpoint
and apoptosis. In vivo, a transactivation-deficient mouse
model showed the importance of the transactivation
activity of p53 in tumor prevention [57]. Nevertheless,
the authors discussed preliminary results that showed
potentially fewer tumors with the mutant transgenic mice
than with the p53 null mice. However, these data might be
not significant because the mice were not sufficiently old to
enable a definitive conclusion. Moreover, the authors
demonstrated a constitutive accumulation of the mutant
protein. Based on experiments cited previously, this
accumulation should repress HR in an unregulated way.
Because inhibition of RAD51-dependent HR stimulates
tumorigenesis [58], it is not possible from these experi-
ments to evaluate the relative parts of the transactivation
or the HR repression roles of p53 in tumor protection.
Remarkably, precise control of HR equilibrium is essential
for genetic stability because both HR stimulation and
repression lead to genome instability.
The treatment of mice with a chemical compound that
inhibits the transcriptional and apoptosis functions of p53
did not lead to tumor formation, even after the mice were
irradiated [59]. More directly, null p21 mouse models are
defective in G1 checkpoint control and do not develop
spontaneous malignancies [60]. It is thus tempting to
speculate that p53 can also be involved in tumor protec-
tion, via an additional mechanism.
HR can lead to genome rearrangements via recombi-
nation between dispersed repetitive sequences (Figure 1).
Moreover, increased levels of RAD51 protein, which
stimulates HR and chromosome instability [61], have
been reported in tumor cells [62]. Therefore, the control of
HR excess represents a good candidate for this additional
p53 tumor protection process. If it was not relevant, one
might predict that a significant portion of p53 tumor
mutants have retained the ability to repress HR, which
based on published data does seem to be the case
[14,18,23]. By contrast, the A135Vp53 mutant, which
retains its HR suppression function [26], is not tumori-
genic under all conditions and retains the tumor suppres-
sing activity of wt p53 in some circumstances [63].
Conclusions
As ‘guardian of the genome’, p53 appears to wear several
hats. First, it controls cell cycle and apoptosis indirectly
via its transcription activity. Second, it regulates genome
plasticity by controlling HR directly at both the initial
and the late stages via its interactions with HR proteins
and intermediate structures (Figure 4). The raison d’eˆtre
of both roles is the same: preventing the damaged
DNA matrix from participating in replication to secure
genome stability.
Two mechanisms can account for the repression of
RAD51-dependent HR at a molecular level: (i) inhibition or
reversion of strand exchange, at an early stage of HR; and
(ii) recognition and reversion of HR intermediates, at a late
stage of HR (Figure 4b,c). Each of these two mechanisms
involves different domains of p53: the core domain for the
early steps and the C-terminal domain for the late steps.
The MMR system and p53 show a common anti-HR
activity; both have been shown to correct mismatches with
complementary specificities and to bind to cruciform junc-
tions. They might represent complementary backup sys-
tems to avoid recombination excess, which can lead to
translocation or gene inactivation (Figure 1).
However, the impact of HR stimulation (and the role of
p53 in such a process) on tumorigenesis remains to be
evaluated directly. Nevertheless, the direct role of p53 in
genome plasticity control sheds new light on an important
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dimension of the complex function(s) of p53 in the cellular
response to DNA damage. Precise characterization of the
interactions between p53 and HR that are involved in
human diseases and the consequences for chromosomal
stability and tumorigenesis constitutes a major and
exciting challenge for future studies.
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